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Abstract (Word count: 249 words)

2

Background Preventing PE is a priority after major musculoskeletal surgery. There is

3

discrepancy in published data regarding the influence that anticoagulation has on the

4

incidence of PE following joint arthroplasty. The American College of Chest Physicians

5

guidelines recommend administration of oral anticoagulants (warfarin), aiming for an

6

INR level between two and three. However, recent studies show aggressive

7

anticoagulation (INR greater than two) can lead to hematoma formation and increased

8

risk of subsequent infection.

9

Questions/purposes We asked whether an INR greater than two is protective against PE.

10

Patients and Methods We identified 9,112 patients with 10,122 admissions for joint

11

arthroplasty between 2004 and 2008. All patients received warfarin for prophylaxis,

12

aiming for an INR level of two or below. Of the 10, 122 admissions, we assessed 609

13

(6%; 609/10122) for PE using CT, VQ scan, or pulmonary angiography. Of these, 163

14

patients (1.6%; 163/10122) had a proven PE.

15

Results Of these 163 patients, 9% (15/163) had an INR greater than two prior to or on the

16

day of work-up compared to 8% (35/446) of patients who were negative. We observed

17

no difference between the INR values in patients with or without PE.

18

Conclusions We found no clinically relevant difference in the INR values of patients who

19

did or did not develop PE. The risk of bleeding should be weighed against the risk of PE

20

when determining an appropriate target INR for each patient, as an INR less than two

21

may reduce the risk of bleeding while still protecting against PE.

AU: Please do not delete query boxes or remove line numbers; ensure you
address each query in the query box.

2
22

Level of Evidence: Level III Therapeutic study. See Instructions to Authors for a

23

complete description of levels of evidence.
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Introduction

25

Pulmonary embolism (PE) is a serious and potentially fatal complication that can develop

26

following total joint arthroplasty (TJA), with an incidence of 1.1 to 1.82% after total knee

27

arthroplasty (TKA) and 0.51 to 0.9% after total hip arthroplasty (THA) [12,18,19].

28

Patients undergoing TJA are considered to be at higher risk for PE. Prevention of PE

29

following orthopaedic procedures continues to be a priority. For this reason, various

30

scientific groups have devised guidelines for implementation of anticoagulation

31

prophylaxis to minimize this complication [10,11].

32

In 2008 the American College of Chest Physicians (ACCP) issued updated guidelines

33

regarding postoperative PE prophylaxis in elective hip or knee arthroplasty [10]. These

34

guidelines endorse the use of low molecular weight heparin (LMWH), fondaparinux, or

35

Vitamin-K antagonists to achieve an international normalized ratio (INR) between two

36

and three. These guidelines, however, make the assumption that deep venous thrombosis

37

(DVT) and PE should be treated as the same entity and that the former is likely to lead to

38

the latter. A recently published study discredited this relationship [16]. Further, the

39

ACCP guidelines do not account for the risk or severity of bleeding complications

40

associated with anticoagulation. At an INR of two to three, the incidence of major

41

bleeding complications ranges from 5.0% to 5.6% after TKA and 0.6% to 1.6% after

42

THA [8,9,17]. In those same studies, the rate of minor bleeding complications following

43

TKA and THA reportedly ranges from 21% to 28% and 4.6% to 13.5%, respectively.

44

With the increased risk of bleeding complications, it is important to understand the

45

effectiveness of therapeutic anticoagulation in minimizing PE. We previously

46

demonstrated the low risk of complications with the use of low-dose warfarin (i.e. aiming
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for an INR less than two) for preventing PE [1]. That study was the basis for

48

implementing the use of low-dose warfarin (aiming for an INR less than two) in patients

49

undergoing TJA in 1990.

50

We therefore asked whether an INR level greater than two, as dictated by the ACCP

51

guidelines, following TJA is protective against PE.

52

Patients and Materials

53

From our institutional database we retrospectively identified 9,112 patients who

54

underwent TJA between January 2004 and June 2008 and had at least a single

55

postoperative INR value available. Those patients who underwent work-up for PE yet

56

did not have an INR value on the day of or prior to scan were excluded. During that

57

same time, we treated 9,973 patients with TJA. Therefore, 861 patients were excluded

58

due to lack of complete data, the demographics of these two groups were investigated

59

(Table 1). The 9,112 patients had an average age of 64 years (range, 11-103 years) and

60

had 10,122 admissions for 11,300 procedures (4,727 primary hips, 5,079 primary knees,

61

803 revision hips, 615 revision knees, and 76 hemiarthroplasties). Patients were followed

62

until discharge from the hospital, on average 6.3 days (range: 2-56 days). Any patients

63

with symptoms indicative of PE were investigated. Since this study observational

64

window ended at discharge, no patients were lost to followup. No patients were recalled

65

specifically for this study; all data was obtained from medical records.

66

The protocol for anticoagulation at our institution throughout the study period consisted

67

of administration of 1000 IU of intravenous heparin at the time of dislocation of the hip

68

during hip arthroplasty and prior to inflation of the tourniquet during knee arthroplasty.
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In addition, we placed patients on oral anticoagulation (warfarin), aiming for an INR

70

level of two or below. Patients continued on the anticoagulation for a period of six weeks.

71

The institutional guidelines are modeled after the recommendations from the AAOS [11]

72

for prevention of PE after TJA. These guidelines were developed without regard for the

73

prevention of DVT. This conflicts with the recommendations made by the ACCP [10],

74

whose means of PE prevention include prophylaxis against DVT. There were variations

75

based on the risk profile of patients for PE and bleeding. We gave patients at higher risk

76

of PE low molecular weight heparin in addition to oral anticoagulation until their INR

77

level reached therapeutic levels. We considered patients at high risk for PE as those with

78

previous PE, polycythemia vera, and those in a hypercoagulable state. On the other hand,

79

we gave patients at high risk of bleeding aspirin for anticoagulation. We considered

80

patients at high risk for bleeding as those with recent cranio-spinal surgery, active gastric

81

ulcer, and hemophilia. Prophylaxis with warfarin involved administration of the drug on

82

the operative day. We monitored the INR daily while the patient was in the hospital, and

83

dosed warfarin according to their INR level. The mean preoperative INR for the entire

84

cohort of 10,122 admissions was 1.09. The median daily postoperative values for INR

85

were 1.13 (range, 0.67-3.04) on postoperative day (POD) zero, 1.24 (range, 0.6-5.8) on

86

POD one, 1.39 (range, 0.4-7.0) on POD two, 1.32 (range, 0.7-5.3) on POD three, 1.33

87

(range, 0.9-5.2) on POD four, and 1.41 (range, 0.8-4.3) on POD five (Fig. 1). The

88

proportion of patients with an INR greater than two was 0.7 %, 0.2%, 6.4%, 3.1%, 4.5%,

89

and 8.6% for the POD zero through five, respectively (Fig. 2). We plotted the percentage

90

of patients who had an INR greater than two in the PE positive and PE negative groups

91

against the day of scan, including the five days before and after the scan. The work-up
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for PE at our institution followed a standard protocol as well. This protocol underwent

93

some modification over time. In general, we first administered oxygen to patients with

94

hypoxia and monitored them very closely (Appendix). If within five to ten minutes of

95

oxygen therapy hypoxia was not resolved, we imaged these patients for PE, which

96

included multi-detector computed tomography (MDCT), VQ scan and, in rare cases,

97

pulmonary angiography. We evaluated patients with other signs suggestive of PE, such

98

as tachycardia, tachypnea, dyspnea, and so on, thoroughly and, based on the judgment of

99

the evaluating internist, subjected them for PE work-up.

100

From among the 10,122 admissions, 600 patients (609 admissions; 6.0 %) were scanned

101

for PE. This subset had an average age of 69 years (range, 24-96 years) and consisted of

102

424 (73.5%) women. These patients had 710 arthroplasty procedures (194 primary hips,

103

428 primary knees, 38 revision hip, 42 revision knee, and eight hemiarthroplasties) in 621

104

admissions. Following work-up for PE, 163 admissions (163/10,122; 1.6%) were

105

positive for PE and included in the positive PE subgroup. Among the 609 admissions

106

that received work-up for PE, the majority (41.2%; 251/609) were scanned on POD 2

107

(Fig. 1). We assessed their daily INR values to identify any variations in their INR

108

relative to the remaining patients who were negative for PE and the entire arthroplasty

109

cohort. We utilized the Charlson comorbidity index [3], as modified by Deyo et al. [5],

110

to assess comorbidities. This index is adjusted for age. Variables describing differences

111

between PE positive and PE negative patients are reported (Table 2). Furthermore, the

112

same variables are reported for patients with a post-operative INR greater than two versus

113

INR less than two (Table 3).
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To analyze the anticoagulation (INR) levels and confounding variables of the three

115

cohorts we utilized a series of statistical tests. First, the data was tested for normality

116

using the Kolmogorov-Smirnov test. Normal continuous data was assessed using the

117

Student’s t-test, and confidence intervals provided clinical significance of variations.

118

Non-normal continuous data was assessed with the Mann-Whitney test, and twenty-fifth

119

and seventy-fifth percentiles were used to represent the variation of data. Chi-squared

120

analysis was used for categorical data. All data analysis was done using SPSS 16.0

121

(Chicago, IL).

122

Results

123

Female gender (p = 0.04), body mass index (p < 0.001), knee replacement (p < 0.001),

124

increasing age (p < 0.001), and an increase in age-adjusted Charlson Index (p < 0.0001)

125

were risk factors for developing PE (Table 2). Type of arthroplasty (revision versus

126

primary) did not predict development of PE. There were no differences between the

127

confirmed PE positive and confirmed PE negative groups with regards to proportion of

128

patients with an INR greater than two on the day of or prior to the work-up (9.2% in PE

129

positive versus 7.9% in PE negative; p = 0.55). On the first day after the scan, the PE

130

negative group tended to have a higher percentage of patients (p = 0.11) with an INR

131

greater than two. On post-scan days three, four, and five, there was a higher percentage

132

(p = 0.009, 0.0001, and 0.0002, respectively) of PE positive patients with an INR greater

133

than two (Fig.3). Patients with confirmed PE had higher INR on POD five (p = 0.02)

134

compared to confirmed PE negative. When aggregating confirmed PE negative patients

135

with patients that were not worked-up, PE positive patients had a higher INR on POD

136

two, three, four, and five (p = 0.012, p = 0.001, p < 0.001, and p < 0.001, respectively).
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Discussion

138

Pulmonary embolism is a dreaded and life-threatening complication that can develop

139

after TJA, with an incidence of 1.1 to 1.82% following TKA and 0.51 to 0.9% after THA

140

[12,18,19]. The 2008 updated ACCP guidelines regarding postoperative PE prophylaxis

141

in musculoskeletal patients [10], endorsed the use of LMWH, fondaparinux, or Vitamin-

142

K antagonists to achieve an INR between two and three. These guidelines, however,

143

assume that DVT is a proxy for PE. Even more, the ACCP guidelines do not consider the

144

risk of severe bleeding associated with anticoagulation, which ranges from 5.0% to 5.6%

145

following TKA and 0.6% to 1.6% after THA [8,9,17], as well as the risk for minor

146

bleeding complications following TKA and THA (21% to 28% and 4.6% to 13.5%,

147

respectively). Safety and low risk of complications with the use of low-dose warfarin

148

(i.e. aiming for an INR less than two) for preventing PE has been demonstrated [1]. We

149

therefore asked whether an INR level greater than two, as dictated by the ACCP

150

guidelines, following TJA is protective against PE.

151

This study is limited by a number of issues. First, while the relatively large size of

152

patients undergoing evaluation for PE adds to its strength, some patients in this study

153

may have received work-up for PE following discharge from the hospital that were not

154

disclosed to their treating surgeon. Second, due to the fact that our observational window

155

was focused on in-hospital data only; incidence of PE may be skewed, and PE occurring

156

up to three or more months post-operatively were not captured. Third, due to the

157

retrospective nature of the study, it is not possible to provide an accurate number

158

(although small) of those patients that deviated from the main anticoagulation protocol

159

(i.e. patients with previous PE, polycythemia vera, and those in a hypercoagulable state)
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who received an alternate anticoagulation protocol. Fourth, there are no set standards in

161

defining PE and it is plausible that some of the emboli seen on lung scans (MDCT) were

162

fat emboli that could not be distinguished from venous emboli. Fifth, not all patients in

163

this study had pulmonary angiography, which is considered the gold standard for

164

diagnosis of PE. Due to the invasive nature of the test and the costs involved, pulmonary

165

angiography is reserved for only a limited number of patients. Furthermore, not all

166

patients included in this analysis underwent work-up for PE. This led us to separate the

167

cohort into three groups (PE positive, PE negative and not scanned). While we make the

168

assumption that asymptomatic patients were PE negative, this cannot be truly confirmed

169

without invasive work-up. Sixth, this study is only evaluating the efficacy of an INR

170

target (less than two) set at our institution. These results do not exclude the possibility

171

that a lower INR target would be as efficacious at preventing PE.

172

This study highlights some important findings. First, the incidence of PE is low (1.6%)

173

and comparable to literature [14,19] using low-dose warfarin, with no fatal PE during the

174

period of this study. Second, there is no correlation between the level of INR and the

175

development of PE. It appears that PE could develop in any patient, including those with

176

an INR greater than two. These findings raise the possibility that either INR fails to

177

measure the efficacy of warfarin as an anticoagulant or that prophylactic anticoagulation

178

has no effect on the incidence of PE. A study, (130,000 patients), demonstrated that the

179

incidence of PE among patients without anticoagulation prophylaxis (0.12%) is the same

180

as those receiving it (0.095%) [13]. Although, there is a division among the orthopaedic

181

surgeons regarding the most effective modality, they agree that some form of VTE

182

prophylaxis is warranted. Some believe that improvements in surgical and anesthesia
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care for patients undergoing TJA have made administration of chemical anticoagulation

184

unnecessary [2].

185

Orthopaedic surgeons consistently take an active role in preventing PE; however, there

186

are key differences between the manner that they and medical physicians approach this

187

complication. First, they observe that 8.9% to 25.6% of TJA patients develop DVT,

188

while only 0.5% to 2.0% developed PE [14,19]. For this reason, the American

189

Association of Orthopaedic Surgeons (AAOS) recommends treating DVT and PE as

190

separate entities. Second, they are committed to minimizing bleeding complications in

191

their surgical patients; these can be as devastating to patients as PE [15]. A study

192

comparing low-dose warfarin with a target INR of 1.5 to two with a historical control

193

group with a target INR of two to three, found no difference in the incidence of DVT, PE,

194

or death [4,7]. Expectedly though, a higher incidence of bleeding complications occurs

195

in the higher target INR group. Major bleeding complications can be a foundation for

196

infection, wound healing problems, functional disability, and prosthetic loosening [7].

197

All of these consequences can lead to reoperation and increase in morbidity and

198

mortality. Third, pneumatic compression boots and aspirin, along with regional

199

anesthesia, are suggested as being non-inferior to chemoprophylactic anticoagulants at

200

preventing PE without the increased bleeding complications [6]. Interestingly, potent

201

anticoagulants like warfarin and LMWH are associated with increased all-cause mortality

202

rates, including PE, when compared to pneumatic compression boots and aspirin [20]. It

203

is from this point of view that the AAOS created the guidelines stating that patients at a

204

standard risk of both PE and bleeding can be given aspirin, LMWH, synthetic

205

pentasaccharides, or warfarin to reach an INR goal of less than or equal to two [11]. A
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previous prospective study from this institution that involved performing preoperative

207

and postoperative VQ scans in a consecutive series of patients undergoing TJA found that

208

low dose warfarin (with an INR goal of less than two) is effective at minimizing

209

development of PE, with a low (2.4%) bleeding complication [1]. Based on these

210

findings, we have used low-dose warfarin as a prophylaxis for prevention of PE in our

211

patients over the last two decades.

212

The most pertinent finding of this study is that an INR greater than two does not appear

213

to protect against PE. Thus, implementing the recommendations of ACCP [10] in aiming

214

for an INR greater than two may not protect these patients against PE, while exposing

215

them to the undue risk of bleeding and all untoward consequences that may ensue [8,9].

216

Despite the limitations, we believe our data and that in the literature casts doubt on the

217

belief that administration of aggressive anticoagulation can and does protect patients

218

against development of PE.
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Legends

Fig. 1 Graph shows median INR versus day of surgery (columns, left axis) and
histogram displaying PE work-up day of scan relative to POD (area curve; right axis).
POD two was the maximum day of scans for both positive and negative PE patients.
Fig. 2 Graph shows percentage of patients with INR greater than two from preoperative
to POD five.
Fig. 3 Graph shows percentage of patients with INR greater than two by day of scan
(lines; right axis), as well as median INR related to the day of scan (columns; left axis).
Day of scan is 0, the five days before the scan is in reverse chronological order as -1
through -5, and the five days after the scan is days 1 through 5. Displays median values
between positive PE and negative PE patients. On the day of scan, there was no
difference (p = 0.63) between INR values. PE positive patients had higher INR values on
post-scan days three, four, and five (p = 0.009, p < 0.001, and p < 0.001, respectively).
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